secwatch.observer — SEC 8-K summary
======================================

Issuer:     USANA HEALTH SCIENCES INC (USNA)
CIK:        0000896264
Form:       8-K
Filed at:   2022-07-06T23:59:59+00:00
Accession:  0001157523-22-000820
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

USANA preliminary Q2 net sales ~$265M (down 21% YoY); cuts FY2022 guidance sharply
--------------------------------------------------------------------------------

- Preliminary Q2 net sales ~$265M vs $337M a year ago; EPS ~$1.05 vs $1.87.
- FY2022 guidance cut: net sales now $1.015-1.065B (prev. $1.1-1.2B); EPS $3.85-4.45 (prev. $5.00-5.70).
- COVID lockdowns in China and regional sales program disruption drove weaker Q2 results.
- CEO Kevin Guest cites lower program participation and inflationary pressures; final Q2 results due July 26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/896264/000115752322000820/0001157523-22-000820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/896264/000115752322000820/a52772859.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer